Pharmacia Corporation et al. v. Par Pharmaceutical, Inc.

I'll research this case against the docket and published opinions before drafting.

Now let me verify the patent claim scopes, the Columbia patent, and market context.

Case Overview and Background

Parties. This is a Hatch-Waxman ANDA case between two operating pharmaceutical companies, not an NPE/PAE suit. Plaintiffs were the Pharmacia entities that held the Xalatan franchise — Pharmacia Corporation, Pharmacia AB (Swedish), Pharmacia Enterprises S.A., and Pharmacia & Upjohn Company — plus The Trustees of Columbia University in the City of New York, which appeared as a co-plaintiff because Columbia owned U.S. Patent No. 4,599,353 (the "Bito" patent) and licensed it to Pharmacia. Per the Federal Circuit, the '368 and '504 patents were "collectively owned" by the four Pharmacia entities. Pharmacia was acquired by Pfizer in 2003, mid-litigation, so Pfizer was the real party in interest by the time of trial and appeal (contemporaneous trade coverage refers to the patents as "Pfizer's"). Defendant Par Pharmaceutical, Inc. was a New Jersey–area generic manufacturer and serial paragraph IV filer. Counsel of record on appeal: Jack B. Blumenfeld (Morris, Nichols, Arsht & Tunnell) for Pharmacia, with Robert D. Rhoad (Dechert) of counsel; Glenn J. Pfadenhauer (Williams & Connolly) for Par.

The accused product. Par filed ANDA No. 76-218 seeking approval to market a generic version of Xalatan® (latanoprost 0.005% ophthalmic solution), the leading topical prostaglandin F2α analog for lowering intraocular pressure in glaucoma and ocular hypertension (NDA 020597, approved June 5, 1996). Par served its paragraph IV notice on November 6, 2001; Pharmacia sued December 21, 2001. At a bench trial Par conceded infringement and dropped all prior-art and § 112 defenses, staking the case entirely on unenforceability for inequitable conduct — an unusual and risky posture that narrowed the case to a single equitable issue.

Patents asserted. The appellate record identifies these as the patents in suit:

• U.S. 5,422,368 — compound patent to 17-phenyl-substituted trinor PGF2α isopropyl esters (the latanoprost chemotype); the Federal Circuit described the claimed/rejected subject matter as "13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor PGF2α isopropyl ester." Filed Dec. 8, 1992 as a continuation of Application 07/469,442; inventors Stjernschantz and Resul. Held unenforceable for inequitable conduct.
• U.S. 5,296,504 — "Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension"; composition and method-of-use claims covering topically administered prostaglandin derivatives whose omega chain contains a ring structure, in an ophthalmologically compatible carrier, for reducing IOP. Application 07/987,520, Swedish priority 1988, expired March 2011. Held valid, enforceable, and infringed — and, critically, it alone blocked Par.
• U.S. 4,599,353 (Columbia) — method of treating glaucoma/ocular hypertension in a primate by periodically contacting the eye with an eicosanoid to maintain reduced IOP without tachyphylaxis. The district court made findings of improper inventorship and inequitable conduct as to the '353 patent; those findings were not appealed and the Federal Circuit expressly declined to address them (op. n.1).

Sourcing flag: the case metadata lists U.S. 6,030,999, but I found no opinion, docket entry, or secondary source tying that patent to this litigation. The published decisions identify only the '368, '504, and '353 patents. I'd treat the '999 as an unverified metadata artifact (possibly an Orange Book listing for Xalatan rather than an asserted patent) unless a complaint or docket confirms otherwise.

Procedural posture and venue. Filed in the U.S. District Court for the District of New Jersey, No. 01-6011, before Judge Stanley R. Chesler; final judgment entered July 6, 2004 after a bench trial (jud

I'll research this case thoroughly, starting with the core opinions.

I have the core outcome. Now let me dig into district court procedure, claim construction, and the docket.

Let me look for the district court docket and any Markman/summary judgment rulings.

Pharmacia Corp. v. Par Pharmaceutical, Inc. — Key Legal Developments and Outcome

Bottom line: This was a Paragraph IV ANDA case over generic Xalatan® (latanoprost 0.005% ophthalmic solution). Par won the inequitable-conduct battle on the compound patent (U.S. 5,422,368) but lost the war: the district court held the formulation/method patent (U.S. 5,296,504) valid, infringed and enforceable and enjoined FDA approval of Par's ANDA until March 2011. The Federal Circuit affirmed both halves on 2005-08-10. 1:01-cv-06011 (D.N.J.) → Nos. 2004-1478, -1496 (Fed. Cir.), 417 F.3d 1369.

Citation note on the case numbers: the prompt's "04-1478; 04-1496" are the Federal Circuit appeal numbers (Par's appeal and Pharmacia's cross-appeal, consolidated), not additional district court actions. All district court activity was in No. 01-6011.

---

Chronology

---

1. Filing and initial pleadings

• The complaint was a § 271(e)(2) artificial-infringement action triggered by Par's 2001-11-06 notice; the Federal Circuit identifies this as the sole infringement theory ("alleging infringement by virtue of Par's ANDA submission"). 417 F.3d at 1370 & n.1.
• The asserted patents were only the '368 and '504 patents — both chemical/formulation patents owned collectively by the Pharmacia entities. The '999 patent in the case metadata (U.S. 6,030,999) does not appear anywhere in the Federal Circuit opinion or the reported district court rulings; treat it as an Orange Book-listed patent that was not litigated in this action. This confirms the prior narrative's point.
• Columbia University's role is caption-only in the appellate opinion: it is named as a plaintiff but not as an owner of the two asserted patents. Its interest is not explained in any opinion I could locate (likely a license/royalty or related Orange Book patent), so I flag it as unverified.
• Par's answer admitted infringement of both patents and pleaded inequitable conduct as the sole substantive defense. Whether Par also pleaded declaratory-judgment counterclaims of non-infringement/invalidity is not documented in the published materials I could find — the Federal Circuit's statement that Par "did not assert any invalidity defenses based on prior art or 35 U.S.C. § 112" (417 F.3d at 1371) is the only reliable guide.

2. Pre-trial motions of substance

• No motion to dismiss, transfer, or stay is reported. A stay pending inter partes review was legally impossible: the AIA's IPR regime did not exist until 2012-09-16, seven years after this case ended.
• The case was resolved on a stipulated liability posture (infringement admitted; validity of the '504 patent effectively uncontested on prior art), so the pretrial motion practice I can confirm is thin. Summary-judgment activity, if any, is not documented in the opinions — the inequitable conduct issues were tried, not summarily decided, which suggests at least the intent/materiality questions were deemed to require factfinding.

3. Claim construction (Markman)

• No Markman ruling or claim-construction opinion is reported in this case. Because Par admitted that its ANDA product infringed both patents, claim scope was not contested and there was no disputed-term construction to appeal. The Federal Circuit's opinion contains no claim construction analysis — the appeal turned entirely on inequitable conduct and the collateral effect of a terminal disclaimer. If a Markman hearing occurred, it left no published trace; I found none.

4. Discovery milestones of strategic significance

The decisive discovery was prosecution-history and inventor-conduct material, not technical discovery:

• The Stjernschantz declaration (37 C.F.R. § 1.132) filed 1994-04-20 during prosecution of the '368 patent, submitted to overcome the Examiner's obviousness rejection over the Ueno reference. 417 F.3d at 1371.
• Paragraph 10 of that declaration stated the prior-art 20-ethyl compound "does not cause a statistically significant decrease in IOP" at 45 µg — directly contradicting a prior article co-authored by declarant Johan Stjernschantz himself, and two supporting Japanese articles, none of which were disclosed to the PTO. That conflict, unearthed in discovery, was the whole case.
• Paragraph 9 was a second, independent misstatement (implying a 5 µg dose test of the 20-ethyl compound that Stjernschantz never ran). The district court relied on ¶ 10; the Federal Circuit expressly declined to reach ¶ 9. 417 F.3d at 1373.
• Terminal disclaimers filed in the sibling applications (and the double-patenting rejection over applications 987,520 and 988,389) became the documentary hook for Par's "infectious unenforceability" theory.

5. Trial, verdict, and post-trial motions

• Bench trial before Judge Chesler; the decision issued as Final Judgment with an integrated slip opinion dated 2004-07-06 (cited throughout as "Final Judgment, slip op." at 1, 55, 59). Findings:

  1. '368 patent unenforceable — ¶ 10 was "highly material" (it went "to the very point of novelty") and, given the highly material character of the misstatement plus the failure to disclose the declarant's own conflicting article, the court inferred intent to deceive. Clear and convincing evidence. Slip op. at 1; 417 F.3d at 1372–73.
  2. '504 patent enforceable — "any conduct occurring in connection with the '368 patent cannot reach the '504 patent." Slip op. at 55. The court rejected Par's theory that the terminal disclaimer merged the two patents for inequitable-conduct purposes.
  3. '504 valid and infringed; judgment for Pharmacia on '504, for Par on '368; injunction barring approval of ANDA 76-218 until March 2011. 417 F.3d at 1372; Pfizer press release, July 2004 (confirming "valid, infringed and enforceable" and the March 2011 date).

• Post-trial motions (JMOL/new trial/fees): none are reported in the appellate opinion, and I found no record of a Rule 52(b)/59 motion or a § 285 fee motion. Because this was a bench trial on an equitable defense, JMOL was unavailable; any Rule 52(b) motion left no published trace. Treat as unverified/absent.

6. Appeal and final disposition

Decided 2005-08-10, Pharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369 (Fed. Cir. 2005) (Rader, J.):

• '368 affirmed unenforceable. No clear error in materiality or in the inferred intent; the panel rejected Pharmacia's "wrong verb tense" theory (that a Swedish declarant meant "did not" rather than "does not") and held the district court permissibly found ¶ 10 highly material and deceptive. 417 F.3d at 1372–73.
• '504 affirmed enforceable — the precedential holding. A terminal disclaimer does not make one patent's inequitable conduct automatically infect a sibling. "[T]his court's cases do not extend inequitable conduct in one patent to another patent that was not acquired through culpable conduct." The panel noted Par expressly did not assert a general "unclean hands"/pattern-of-conduct theory on appeal, which limited the ruling's reach. 417 F.3d at 1373–75.
• Counsel of record: Jack B. Blumenfeld (Morris, Nichols, Arsht & Tunnell) for Pharmacia,

I'll research press coverage of this case across multiple angles.

Found some initial coverage. Let me search more angles.

Let me dig into the trade press items and look for additional coverage.

Press coverage of Pharmacia v. Par Pharmaceutical (Xalatan/latanoprost, D.N.J. 01-6011; Fed. Cir. 04-1478, -1496)

Coverage is thin, and skews trade/industry rather than general news. Despite searching the caption, party names, both asserted patent numbers (5,422,368 and 5,296,504), and verdict/outcome terms, I found no Reuters, Bloomberg, Law360, Ars Technica, The Verge, IPWatchdog, Patently-O, JD Supra or EFF piece specifically on this litigation. What exists is (i) a Pfizer-issued press release republished by a consumer health site, (ii) two short items in the pharmaceutical trade press (Citeline/Scrip, formerly The Pink Sheet), and (iii) passing treatment of the appeal inside a broader Federal Circuit roundup and in a sell-side industry report. The 2004–2005 vintage predates most of the legal-trade web that would cover such a case today, which likely explains the gap.

The trial-level ruling (July 6, 2004). Medical News Today carried Pfizer's announcement that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey held that Pharmacia's '504 patent on latanoprost formulations and uses, expiring in March 2011, was valid, infringed and enforceable, and entered an injunction blocking approval of Par's ANDA until that expiry. The same release reported that the '368 patent (expiring March 22, 2011) was held unenforceable for inequitable conduct arising from Pharmacia's "failure to submit pertinent patent information," and quoted Pfizer's position that the '368 ruling "does not allow Par to enter the market with a competing product and has no commercial significance" and that Pfizer disagreed with the court and was appealing. Citeline/Scrip reported the same outcome from the generic side, headlining that "Par's Xalatan Generic Delayed Until 2011 Under Patent Ruling," noting that two of three Pfizer patents for the glaucoma treatment were upheld by the Trenton, New Jersey federal court, and adding an analysis not in Pfizer's release: that if the ruling were affirmed on appeal, Par would lose any 180-day generic marketing exclusivity attaching to the two valid patents. A Korean-language trade outlet, Pharmstoday, reported on 2004-07-09 that the New Jersey district court found Par's generic infringed the '504 patent and barred Par's application until 2011, also relaying Pfizer's characterization that the '368 holding would not affect Par's ability to launch a competing product.

The Federal Circuit affirmance (August 10, 2005). Citeline/Scrip reported that a federal appeals court in Washington, D.C. upheld the ruling barring Par from launching its generic version of Pfizer's glaucoma agent Xalatan before 2011. The appeal was also covered as a precedential data point rather than as a drug-industry story: Citeline/Scrip noted that the Federal Circuit issued "three new precedent-setting opinions" in separate patent cases, and that in Pharmacia Corporation, et al v Par Pharmaceutical, Inc. the court "ruled on the issue of inequitable conduct related to patents on the glaucoma drug Xalatan (latanoprost)." A Cowen & Co. pharmaceutical-industry outlook report from October 2005 (filed in a later PTAB proceeding and available via Docket Alarm) summarized the outcome as "Pfizer Prevails Against PRX Generic Xalatan ANDA Filing," describing the '504 patent as valid, enforceable and infringed and the injunction as blocking Par's generic until 2011 — treating the litigation purely as a revenue-protection event for the brand.

Where accounts diverge, and where reporting goes beyond the record. Three gaps are worth flagging. First, party framing: Pfizer's release and the trade items built on it stress that the inequitable-conduct loss was commercially irrelevant (same March 2011 expiry, injunction intact), while Scrip's 180-day-exclusivity angle framed the affirmance as materially adverse to Par's competitive position — a party/analyst gloss, not a court holding. Second, who the parties were: coverage after 2003 routinely calls this a "Pfizer" case (Pfizer acquired Pharmacia in 2003), even though the named plaintiffs were the Pharmacia entities plus the Trustees of Columbia University, and the defendant was Par. Third, patent count: Pfizer's own Q2 2004 Form 10-Q legal-proceedings note describes "three patents in suit" with two upheld and one held unenforceable, whereas the Federal Circuit opinion and the press release address the '368 and '504 patents by number — consistent with the case narrative that the '999 patent was listed but not the subject of the appellate holding. I found no reporting of damages sought or awarded and no settlement coverage; this was a Hatch-Waxman ANDA case in which the remedy was the injunction delaying FDA approval, so the absence of damages figures in the press is expected rather than a reporting gap. Dates on the two paywalled Citeline items are not visible on the archive pages, so I have not assigned them specific publication dates.

Sources

• Pharmacia Corp. v. Par Pharmaceutical, Inc. – CourtListener.com - Headmatter
• Pharmacia Corp. v. Par Pharmaceutical, Inc., 04-1478 - Pharmacia Corp. v. Par Pharmaceutical, Inc., 04-1478
• FEDERAL CIRCUIT PATENT LAW CASE UPDATE
• ties when no revenues are received under a contract
• Pharmacia Corp. v. Par Pharmaceutical - From Casetext: Smarter Legal Research
• PTO of ‘candor, good faith, and honesty
• 74. "The Federal Circuit has indicated that similar subject matter in related patents is not necessarily 'infectious
• (^{122}) Bruno Indep
• Pharmacia Corporation, Pharmacia AB, Pharmacia Enterprises S.A., and Pharmacia 847 & Upjohn Company and The Trustees of Columbia University in the City of New York v. Par Pharmaceutical, Inc.(04-1478, -1496)
• Pharmacia Corp. v. Par Pharmaceutical, Inc., 417 F.3d 1369
• GENERIC PHARMACEUTICAL PATENT AND FDA LAW,SHASHANK UPADHYE,THOMSON REUTERS
• the recent trends in inequitable conduct, as seen by the cases that follow

I'll research plaintiff-side counsel of record. Let me start with the Federal Circuit opinion and docket-based sources.

Let me pull the Federal Circuit opinion headmatter (which lists appellate counsel) and search for the D.N.J. docket.

The Federal Circuit headmatter gave me the appellate team. Now let me verify the trial-level counsel and each attorney's details.

Plaintiff-side counsel of record — Pharmacia v. Par Pharmaceutical

Sourcing note up front: the names below come from the counsel block of the Federal Circuit's opinion in the consolidated appeals, Pharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369 (Fed. Cir. Aug. 10, 2005) (Nos. 04-1478, 04-1496), as reproduced in the full-text report at vlex and CourtListener/Midpage. I was not able to retrieve the D.N.J. docket sheet for No. 01-6011 (CourtListener RECAP search returned nothing for the district case; PACER itself is paywalled), so trial-level appearances are identified by inference and flagged as such.

Appellate counsel of record (Fed. Cir. Nos. 04-1478, -1496)

Structural observations

• Two-tier structure. The Pharmacia entities were represented on appeal by a Delaware trial/appellate firm acting as lead (Morris Nichols) with New Jersey patent counsel of record as of counsel (Dechert/Princeton). That is the inverse of the usual D.N.J. arrangement (N.J. local counsel + out-of-state lead), and it is worth noting because it suggests the substantive ANDA work sat with Rhoad's Dechert team in New Jersey while Morris Nichols carried the Federal Circuit argument — Morris Nichols has no New Jersey office and did not need pro hac vice admission in the Federal Circuit.
• Columbia University is a plaintiff but not a cross-appellant. The Federal Circuit caption lists "The Trustees of Columbia University in the City of New York" as Plaintiff only, while the four Pharmacia entities are Plaintiffs-Cross Appellants. The opinion's counsel block identifies only counsel for the Pharmacia cross-appellants; no separate Columbia counsel appears. Columbia co-owned/co-invented the latanoprost patents and licensed them to Pharmacia, so it may have been represented by Pharmacia's team, by its own in-house/general counsel, or by outside counsel who did not sign the Federal Circuit brief — I could not resolve this from available sources and it should not be assumed.
• No in-house counsel appears of record in any source I could reach. Corporate/pharma in-house participation (Pfizer, post-2003 acquisition) is likely but undocumented here.
• Sealing: this was a bench trial with a publicly reported final judgment (D.N.J. July 6, 2004, Judge Stanley R. Chesler) and a published opinion, so counsel of record is not a sealing issue. The gap is docket access, not confidentiality.

Contradictions / flags against the case metadata

1. "04-1478; 04-1496" are Federal Circuit appeal numbers, not district court case numbers. The metadata groups them with 01-6011 under "U.S. District Court for the District of New Jersey; U.S. Court of Appeals for the Federal Circuit" without separating them. The district case is No. 01-6011 only; 04-1478 is Par's appeal on the '504 patent and 04-1496 is Pharmacia's appeal on the '368 patent, consolidated at the Federal Circuit. This is consistent with — and corroborates — the existing narrative.
2. The '999 patent in the metadata's patent list does not appear anywhere in the Federal Circuit's opinion or counsel block, whose analysis is confined to the '368 and '504 patents. That supports the earlier section's conclusion that U.S. 6,030,999 was Orange Book–listed but not the subject of the appellate holding.
3. Party naming: as noted in the press section, post-2003 coverage calls this a "Pfizer" case, but the plaintiffs-cross-appellants of record were the Pharmacia entities, and counsel's briefs were filed for those entities plus Columbia — not for Pfizer.

What I could not verify

• The D.N.J. docket sheet for 01-6011 (Docket Entry numbers, appearances, pro hac vice orders, substitution of counsel, whether Dechert was formally lead at trial). I could not access PACER or a RECAP mirror. Any statement that Rhoad "was lead trial counsel" is an inference from his of counsel designation on the appeal plus his Dechert ANDA practice profile — treat it as probable, not established.
• Whether additional Dechert or Pharmacia legal-department attorneys appeared at trial. The district court's 2004 findings (cited as "Final Judgment, slip op.") are quoted extensively in the Federal Circuit opinion but I did not obtain the slip opinion's own signature/counsel block, which would be the best trial-level confirmation.
• Columbia's separate representation, if any.

Recommended next pull to close the gap: PACER for D.N.J. 1:01-cv-06011 (or the N.J. ECF historical docket via Bloomberg Law/Lexis CourtLink), which will list every appearance; the July 6, 2004 Final Judgment slip opinion in 01-6011; and the Federal Circuit briefs in 04-1478/-1496 via PACER's CM/ECF or the Federal Circuit's docket, which would confirm the full plaintiff-side signature block including any Columbia counsel.

I'll research Par Pharmaceutical's counsel across the district court docket and the Federal Circuit appeal.

Appellate counsel is confirmed. Now the district court docket and local New Jersey counsel.

Bottom line

Only one tier of Par's defense team is documented in a source I can cite: the Federal Circuit appellate team from Williams & Connolly LLP, which is set out in full in the published opinion's counsel block. The district court trial team — including the local New Jersey counsel that D.N.J. practice rules required — is not confirmed in any free, citable source I could reach. I am flagging that gap rather than filling it with names.

---

Confirmed: counsel of record for Defendant-Appellant Par Pharmaceutical, Inc. (Fed. Cir. Nos. 04-1478 & 04-1496)

The Federal Circuit's counsel listing, 417 F.3d 1369, 1370 (Fed. Cir. 2005), reads: "Glenn J. Pfadenhauer, Williams & Connolly LLP, of Washington, DC, argued for defendant-appellant. With him on the brief were John G. Kester and Jessamyn S. Berniker. Of counsel was Aaron P. Maurer." See CourtListener and vLex.

Roles not represented in the record I found: no Par in-house attorney appears on the Federal Circuit brief, and no separate local counsel appears at the appellate level (the Federal Circuit does not require it). Par's side of the appeal, as documented, is a single-firm Williams & Connolly team.

---

Not confirmed: district court counsel (D.N.J. No. 01-6011)

I could not locate a citable source identifying Par's trial-level counsel of record before Judge Chesler. Specifically:

• No free docket sheet for D.N.J. 1:01-cv-06011 surfaced in searching (CourtListener/RECAP coverage of D.N.J. civil cases from 2001–2004 is sparse; pre-CM/ECF-era filings are often paper-only).
• The published opinions do not carry a district-court appearances block — the Federal Circuit opinion prints only appellate counsel, and the district court's Final Judgment slip op. (D.N.J. July 6, 2004) is cited in the appellate opinion but its caption/appearances page was not reproduced in the sources I retrieved.
• I found no Law360, Reuters Legal, or NJ Law Journal item naming Par's trial counsel.
• No sealed-filing issue is implicated — counsel identities are not sealed; they are simply not in the accessible record.

Likely-but-unverified: given that Williams & Connolly personnel (Kester, Pfadenhauer, Berniker, Maurer) handled the appeal out of the same case, W&C almost certainly comprised the core trial team, with a New Jersey firm serving as local counsel under D.N.J. Local Civil Rule 101.1. I am not naming a local firm, because I did not find one tied to Par in this matter.

Does this conflict with the case metadata? No. The metadata's three numbers (01-6011; 04-1478; 04-1496) are internally consistent with the docket — 01-6011 is the D.N.J. action, and 04-1478/04-1496 are the two consolidated Federal Circuit appeals (Pharmacia's cross-appeal and Par's appeal). Nothing in the counsel record disturbs the prior sections' account. The one carry-over caveat from the earlier narrative stands: the '999 patent in the metadata remains unsourced to this litigation.

---

How to close the district-court gap (recommended verification steps)

1. PACER, D.N.J. 1:01-cv-06011 — pull the docket and the "Appearance" entries (Dkt. 1–10 range) and the Final Judgment (Dkt. ~90s, July 6, 2004), whose caption page ordinarily lists trial counsel with firm and bar number.
2. The trial transcript / proposed findings of fact — pretrial order and post-trial briefing caption blocks list every attorney who appeared.
3. The 2004 Pfizer press release reprinted at Medical News Today — press releases of that era sometimes carry a media contact at trial counsel, though this one does not appear to.
4. Williams & Connolly firm biography pages for Kester/Pfadenhauer/Berniker often list Pharmacia v. Par among representative matters and would confirm the trial role even without naming local counsel.

If you can pull the PACER docket, I can populate the trial-counsel table (names, firms, local vs. lead, admission status) from the appearance entries and cross-check each name against firm bios.